Intrexon Corp (XON) Short Interest Up 6.1% in March

Intrexon Corp (NYSE:XON) saw a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 35,056,156 shares, an increase of 6.1% from the February 28th total of 33,044,618 shares. Currently, 73.7% of the shares of the stock are sold short. Based on an average trading volume of 5,093,780 shares, the short-interest ratio is currently 6.9 days.

In other news, major shareholder Randal J. Kirk sold 95,241 shares of Intrexon stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $0.65, for a total transaction of $61,906.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Thomas D. Reed sold 225,500 shares of Intrexon stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $4.18, for a total transaction of $942,590.00. Following the sale, the insider now owns 96,280 shares of the company’s stock, valued at approximately $402,450.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 362,419 shares of company stock valued at $1,032,421. Insiders own 48.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of XON. Quantamental Technologies LLC acquired a new position in Intrexon during the fourth quarter valued at approximately $28,000. Truvestments Capital LLC acquired a new position in Intrexon during the first quarter valued at approximately $32,000. Valeo Financial Advisors LLC grew its holdings in Intrexon by 60.9% during the first quarter. Valeo Financial Advisors LLC now owns 10,569 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 4,000 shares during the period. Amalgamated Bank acquired a new position in Intrexon during the fourth quarter valued at approximately $70,000. Finally, Addison Capital Co acquired a new position in Intrexon during the first quarter valued at approximately $81,000. Hedge funds and other institutional investors own 84.92% of the company’s stock.

NYSE XON traded down $0.33 during trading on Friday, reaching $4.11. 20,775,552 shares of the stock traded hands, compared to its average volume of 2,429,209. Intrexon has a fifty-two week low of $3.95 and a fifty-two week high of $19.94.

XON has been the subject of several analyst reports. Zacks Investment Research upgraded shares of Intrexon from a “hold” rating to a “strong-buy” rating and set a $8.75 price target for the company in a research report on Saturday, January 12th. Northland Securities cut shares of Intrexon from an “outperform” rating to a “market perform” rating in a report on Friday, March 1st. Finally, JMP Securities restated a “buy” rating and set a $43.00 price objective on shares of Intrexon in a report on Wednesday, March 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $34.00.

ILLEGAL ACTIVITY WARNING: “Intrexon Corp (XON) Short Interest Up 6.1% in March” was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/04/21/short-interest-in-intrexon-corp-xon-increases-by-6-1.html.

Intrexon Company Profile

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Recommended Story: How is the LIBOR rate calculated?

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.